Appeals court hears bid to curtail access to medication abortion

A federal appeals court recently deliberated on a case that could drastically limit access to medication abortion nationwide, including in states that strongly support reproductive rights. The judges questioned attorneys from Louisiana, the FDA, and pharmaceutical companies involved in the medication mifepristone. If the court rules against current regulations, it could effectively ban this method of abortion, which is crucial for many seeking early termination options. This case is significant because it could redefine reproductive healthcare access across the country.